Lathrop Investment Management Corp Sells 4,874 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

Lathrop Investment Management Corp trimmed its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 16.1% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 25,414 shares of the medical research company's stock after selling 4,874 shares during the period. Lathrop Investment Management Corp's holdings in Charles River Laboratories International were worth $5,006,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in the stock. Tortoise Investment Management LLC increased its stake in shares of Charles River Laboratories International by 77.0% in the second quarter. Tortoise Investment Management LLC now owns 131 shares of the medical research company's stock worth $27,000 after acquiring an additional 57 shares during the period. Wolff Wiese Magana LLC acquired a new position in Charles River Laboratories International in the 3rd quarter valued at about $32,000. Assetmark Inc. boosted its stake in Charles River Laboratories International by 1,153.3% during the third quarter. Assetmark Inc. now owns 188 shares of the medical research company's stock worth $37,000 after buying an additional 173 shares during the period. Whittier Trust Co. of Nevada Inc. boosted its holdings in Charles River Laboratories International by 219.3% during the 2nd quarter. Whittier Trust Co. of Nevada Inc. now owns 281 shares of the medical research company's stock valued at $58,000 after acquiring an additional 193 shares during the period. Finally, Covestor Ltd raised its stake in shares of Charles River Laboratories International by 40.9% in the third quarter. Covestor Ltd now owns 327 shares of the medical research company's stock valued at $65,000 after acquiring an additional 95 shares in the last quarter. 98.91% of the stock is currently owned by institutional investors.

Charles River Laboratories International Price Performance

Charles River Laboratories International stock traded up $3.71 on Friday, reaching $197.90. The company's stock had a trading volume of 230,121 shares, compared to its average volume of 623,483. Charles River Laboratories International, Inc. has a twelve month low of $176.48 and a twelve month high of $275.00. The company has a market cap of $10.12 billion, a price-to-earnings ratio of 24.33, a PEG ratio of 4.80 and a beta of 1.38. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.14 and a current ratio of 1.48. The business's fifty day moving average price is $195.05 and its 200 day moving average price is $206.34.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last released its quarterly earnings data on Wednesday, November 6th. The medical research company reported $2.59 EPS for the quarter, beating analysts' consensus estimates of $2.43 by $0.16. The business had revenue of $1.01 billion during the quarter, compared to analysts' expectations of $975.99 million. Charles River Laboratories International had a net margin of 10.44% and a return on equity of 14.29%. The firm's quarterly revenue was down 1.6% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.72 EPS. Equities analysts expect that Charles River Laboratories International, Inc. will post 10.19 earnings per share for the current fiscal year.

Charles River Laboratories International declared that its Board of Directors has authorized a share repurchase program on Wednesday, August 7th that allows the company to repurchase $1.00 billion in outstanding shares. This repurchase authorization allows the medical research company to reacquire up to 9.6% of its stock through open market purchases. Stock repurchase programs are generally a sign that the company's leadership believes its shares are undervalued.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on CRL. UBS Group raised their price objective on Charles River Laboratories International from $240.00 to $250.00 and gave the stock a "buy" rating in a report on Thursday, November 7th. Barclays decreased their target price on Charles River Laboratories International from $230.00 to $210.00 and set an "equal weight" rating on the stock in a research report on Thursday, August 8th. CLSA lowered Charles River Laboratories International from a "hold" rating to an "underperform" rating and set a $164.00 target price on the stock. in a research note on Monday. Baird R W downgraded shares of Charles River Laboratories International from a "strong-buy" rating to a "hold" rating in a report on Thursday, August 8th. Finally, StockNews.com lowered Charles River Laboratories International from a "buy" rating to a "hold" rating in a research note on Thursday, November 7th. Three analysts have rated the stock with a sell rating, eleven have given a hold rating and two have issued a buy rating to the company. According to data from MarketBeat.com, Charles River Laboratories International has an average rating of "Hold" and a consensus price target of $214.38.

Insider Transactions at Charles River Laboratories International

In other news, Director Richard F. Wallman sold 6,621 shares of the stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $216.12, for a total value of $1,430,930.52. Following the completion of the sale, the director now owns 12,386 shares of the company's stock, valued at approximately $2,676,862.32. This represents a 34.83 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. 1.30% of the stock is currently owned by corporate insiders.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).